Preparation method of tetrahydropyrrolooxazinone ring
By employing steps such as Yelide [3+2] cyclization and Curtius rearrangement, tetrahydropyrroloxazinone rings can be synthesized safely and efficiently, solving the problem of simultaneously synthesizing tetrahydropyrrole and xazinone rings in existing technologies and providing a new method for drug synthesis.
Patent Information
- Application Number
- CN202311836114.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-28
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2043-12-28
AI Technical Summary
Existing technologies make it difficult to synthesize tetrahydropyrrole and oxazinone rings simultaneously via a single route, and commonly used methods require highly toxic reagents, high pressure, or high-energy reagents, resulting in low safety.
A multifunctional tetrahydropyrrole structure was constructed using the Yelide [3+2] ring closure. The cis configuration of the tetrahydropyrroloxazinone ring was then constructed through the Curtius rearrangement reaction, ester reduction reaction, and alcohol-ester exchange ring closure.
A safe and mild synthetic method has been developed that can simultaneously synthesize tetrahydropyrrole and oxazinone rings, providing a new approach to bicyclic heterocyclic skeletons in drug synthesis.
Smart Images

Figure CN117924316B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of chemical drug preparation, and in particular relates to a method for preparing a tetrahydropyrrolooxazinone ring. Background Art
[0002] 1,3-oxazine-2-one, as a six-membered nitrogen skeleton, is an important structural unit in drug synthesis and has been found to have a variety of drug activities, such as antiretroviral activity and antibacterial effects. In 1998, Efavirenz, developed by DuPont, was approved by the FDA for the treatment of AIDS. It is a special drug against HIV. The core structure of the drug is 1,3-oxazine-2-one. This core structure is also widely used as an important intermediate in the preparation of agricultural chemicals, pesticides, herbicides and chiral auxiliary agents.
[0003] As a five-membered nitrogen skeleton, tetrahydropyrrole is also a well-known structural unit with multiple pharmacological activities. It is widely used in anti-tumor, antibacterial, anti-diabetic, antiviral and other drugs. So far, there are hundreds of marketed drugs and clinical candidate compounds containing tetrahydropyrrole structure. For example, buflomedil hydrochloride (treatment of cerebrovascular disease), piromidic acid (antibiotic, bepridil (calcium antagonist), pyrocaine (local anesthetic), idoxifene (prevention and treatment of osteoporosis and breast cancer), etc.
[0004] In the field of small molecule drugs, researchers have found that polycyclic nitrogen-containing heterocycles often have better biological activity. At present, clinical trials have proven that compounds with a core skeleton of tetrahydropyrrolooxazinone ring have biological activities such as bactericidal, anti-inflammatory, inhibition of non-nucleoside reverse transcriptase, inhibition of phosphodiesterase, anti-thrombotic, and analgesic. At the same time, they are also used to prepare drugs with antimalarial, anti-cancer, herbicidal and insecticidal activities. Therefore, the method of introducing tetrahydropyrrole ring and oxazinone ring has received more and more attention. The tetrahydropyrrolooxazinone ring structure is an important five-membered and six-membered double heterocyclic skeleton unit. The active drug molecules containing this structure show obvious antiviral activity and inhibition of MEK enzyme. The anti-HIV drug Efavirenz (English: Efavirenz), which has been launched on the market, has an oxazinone ring in its core structure; the patent for MEK enzyme inhibitors issued by UCB Pharma SA of Belgium in 2009 also contains a tetrahydropyrrolooxazinone ring in its core structure. At present, there are many methods reported for synthesizing oxazinone rings: using phosgene or triphosgene as a condensing agent to phosgene the β-amino alcohol structure; amino alcohol or amino halogenated hydrocarbons to close the ring under pressurized carbon dioxide; alcohol and carbonyl hydrazine to close the ring under nitrous acid; CDI as a condensing agent to close the ring, but it is necessary to make the amino and hydroxyl groups exposed first. These methods either require highly toxic reagents, or require harsh high-pressure environments, or require high-energy dangerous reagents. Chinese patent CN202310292351.3 discloses a method for preparing 4H-benzo[d][1,3]oxazin-4-one compounds, wherein the reaction conditions are to react at 50-120°C for 12-30h in a carbon monoxide gas atmosphere, which shows that the safety is relatively low. Moreover, the currently disclosed prior art is limited to the synthesis of oxazinone ring structures alone, and there is no report on the method of synthesizing tetrahydropyrrole and oxazinone rings simultaneously through a route. Summary of the invention
[0005] In view of this, the present invention aims to overcome the defects in the prior art and proposes a method for preparing a tetrahydropyrrolooxazinone ring.
[0006] To achieve the above object, the technical solution created by the present invention is implemented as follows:
[0007] A method for preparing a tetrahydropyrrolooxazinone ring, wherein the tetrahydropyrrolooxazinone ring is a cis configuration and has a structure as shown in Formula I
[0008]
[0009] The preparation method includes the following synthetic route 1 or synthetic route 2: synthetic route 1:
[0010]
[0011] Synthesis route 2:
[0012]
[0013] Preferably, the specific steps of step 1 are:
[0014] Maleic anhydride, N-methoxymethyl-N-(trimethylsilyl)benzylamine and trifluoroacetic acid are used as raw materials and dissolved in an organic solvent A to react to obtain compound 1.
[0015] Furthermore, the molar ratio of maleic anhydride, N-methoxymethyl-N-(trimethylsilyl)benzylamine and trifluoroacetic acid is (0.8-1.5):(1.0-2.0):(0.1-1.0), the reaction temperature is 0-10°C, and the organic solvent A is selected from dichloromethane, 1,2-dichloroethane or tetrahydrofuran.
[0016] Preferably, the specific steps of step 2 are:
[0017] Compound 1 is dissolved in organic solvent B, and triethylamine, tert-butyl alcohol and azide are added to mix and a curtius rearrangement reaction is performed to obtain compound 2.
[0018] Furthermore, the molar ratio of compound 1, triethylamine, tert-butanol and azidation reagent is (0.8-1.5):(1.0-3.0):(3.0-10.0):(1.0-3.0); the reaction temperature is step-wise increased from 10-40°C to 90-120°C; the azidation reagent is selected from diphenylphosphoryl azide, sodium azide or trimethylsilane; and the organic solvent B is selected from toluene, tert-butanol or xylene.
[0019] Preferably, the specific steps of step 3 are:
[0020] Compound 2, methanol and a reducing agent are dissolved in an organic solvent C to undergo a reduction reaction to obtain compound 3.
[0021] Furthermore, the molar ratio of the compound 2, methanol and reducing agent is (0.8-1.5):(0.5-3.0):(1.0-3.0), the organic solvent C is selected from tetrahydrofuran, 2-methyltetrahydrofuran or methanol, and the reducing agent is selected from LiBH4, lithium aluminum hydride or lithium sec-butylborohydride.
[0022] Preferably, the specific steps of step 4 are:
[0023] Compound 3 is dissolved in organic solvent D, palladium-carbon catalyst is added, and the benzyl protection is removed under hydrogen environment to obtain compound 4.
[0024] Furthermore, the molar ratio of the compound 3 and the palladium-carbon catalyst is (0.5-1.5): (0.01-1.0); the palladium-carbon catalyst is selected from Pd(OH)2 / C, Pd / C; and the organic solvent D is selected from methanol, ethanol or tetrahydrofuran.
[0025] Preferably, the specific steps of step 5 are:
[0026] Compound 5 is obtained by reacting compound 4 with an amino protecting agent in an organic solvent E under basic conditions.
[0027] Furthermore, the molar ratio of the compound 4 to the amino protecting agent and the base is (0.1-1.5): (1.0-2.0): (1.0-4.0); the amino protecting agent is selected from benzyl chloroformate, di-tert-butyl carbonate, (9H-fluoren-9-yl)methyl chloroformate; the base agent is selected from sodium carbonate, triethylamine or potassium phosphate; the organic solvent E is selected from tetrahydrofuran, dioxane or dichloromethane.
[0028] Preferably, the specific steps of step 6-1 are:
[0029] Compound 5 is dissolved in an organic solvent F and reacted with an organic base and methanesulfonyl chloride to undergo a nucleophilic substitution reaction to obtain compound 6.
[0030] Furthermore, the molar ratio of the compound 5, the organic base and the methanesulfonyl chloride is (0.8-1.5):(1.0-4.0):(1.0-4.0); the organic base is selected from triethylamine, N,N-diisopropylethylamine or dimethylaminopyridine; and the organic solvent F is selected from dichloromethane, tetrahydrofuran or dioxane.
[0031] Preferably, the specific steps of step 6-2 are:
[0032] Potassium tert-butoxide is added to compound 5 in organic solvent G to react and generate compound I.
[0033] Furthermore, the molar ratio of the compound 5 to potassium tert-butoxide is (0.8-1.5):(1.0-4.0); the organic solvent G is selected from tetrahydrofuran, 2-methyltetrahydrofuran or DMF; and the reaction temperature is 0-10°C.
[0034] Preferably, the specific steps of step 7 are:
[0035] Compound 6 was reacted by adding 60% NaH in organic solvent H to obtain compound I.
[0036] Furthermore, the molar ratio of the compound 6 to NaH is (0.8-1.5):(1.0-3.0); the organic solvent H is selected from dimethylformamide, tetrahydrofuran or dimethylacetamide; and the reaction temperature is 0-10°C.
[0037] Compared with the prior art, the present invention has the following advantages:
[0038] (1) The present invention first constructs a multifunctional tetrahydropyrrole structure through ylide [3+2] ring closure, at which time the functional groups on the ring are ensured to be in a cis configuration, and then the functional groups on the ring are subjected to a curtius rearrangement reaction, an ester reduction reaction, and an alcohol ester exchange ring closure to construct an oxazinone ring, and finally synthesize a tetrahydropyrrolo-oxazinone ring bicyclic structure. In addition, when an -OMs group is present, an oxazinone ring can be constructed by the loss of a tert-butyloxycarbonyl (Boc), and finally a tetrahydropyrrolo-oxazinone ring structure with a cis configuration is synthesized.
[0039] (2) The synthesis method adopted by the present invention is efficient, the reagents used are mild and friendly, and the method can simultaneously synthesize tetrahydropyrrole and oxazinone ring bicyclic heterocycles, which provides a new idea and method for constructing an important skeleton of bicyclic heterocycles in drug synthesis. DETAILED DESCRIPTION
[0040] Unless otherwise defined, the technical terms used in the following examples have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. The test reagents used in the following examples, unless otherwise specified, are all conventional biochemical reagents; the experimental methods, unless otherwise specified, are all conventional methods.
[0041] The present invention is described in detail below in conjunction with embodiments.
[0042] Embodiment 1:
[0043]
[0044] The 500mL reaction bottle was replaced with nitrogen three times, SM2 (18.83g, 1.0eq) and DCM (151mL, 8.0vol) were added, the system was cooled to 0-10℃, the temperature was controlled, and a solution of SM1 (50g, 1.01eq) in DCM (15mL, 0.8vol) was added dropwise to the system, and there was no obvious temperature rise during the addition process. After the addition, the system turned yellow-green. Keep the system at 0-10℃, and add a solution of trifluoroacetic acid (2.189g, 0.1eq) in DCM (30mL, 1.6vol). After the addition, remove the ice-water bath, slowly heat to room temperature and react for 24h. Add water (18.83g, 1.0eq), precipitate solid, add EA (35mL, 1.86vol) to the system, and stir for 30min. The filter cake was filtered and rinsed with EA (30 mL, 1.6 vol). The filtrate was discarded and the filter cake was dried at 50° C. for 3 h to constant weight to obtain 34.6 g of a white solid product with a yield of 70%. 1 H NMR (DMSO-d6, 400MHz) δ7.32~7.20(m,5H),3.59(s,2H),3.52(s,3H),3.27~3.17(m,2H),2.96~2.89(m,2H),2.65~2.58(m,2H). LCMS[M+1]=264.16.
[0045] Embodiment 2:
[0046]
[0047] A clean and dry 500mL three-necked flask was replaced with nitrogen three times. SM (15.1g, 1.0eq), toluene (151mL, 10vol), triethylamine (7.5g, 1.3eq), tert-butyl alcohol (21.25g, 5.0eq), DPPA (18.94g, 1.2eq) were added in sequence under an external bath at 30℃, and then the temperature was increased stepwise to 110℃. The reaction was carried out overnight under an external bath at 110℃. After the reaction was completed, the temperature was lowered to room temperature, and the system was concentrated under reduced pressure at 40℃ until no fraction flowed out. A saturated sodium bicarbonate aqueous solution (225mL, 15vol) was added and stirred for 20min. The mixture was extracted three times with DCM (150mL, 10vol), and the organic phases were combined and dried over anhydrous sodium sulfate. The organic phase was purified by DCM / MeOH column chromatography (DCM:MeOH=100:1 to DCM:MeOH=20:1) to give a light yellow solid (12.9 g, yield 67.4%). 1H NMR(CDCl3,400MHz)δ7.34~7.23(m,5H),5.10~4.97(m,1H),4.58~4.40(m,1H),3.67(s,3H),3.63(s,2H),3 .33~3.27(m,1H),3.03~2.99(m,1H),2.87~2.80(m,1H),2.73~2.68(m,1H),2.50~2.45(m,1H),1.42(s,9H). LCMS[M+1]=335.89.
[0048] Embodiment 3:
[0049]
[0050] A clean and dry 500mL three-necked flask was replaced with nitrogen three times, and SM (7g, 1.0eq), THF (49mL, 7vol), methanol (1.174g, 1.75eq), and LiBH4 (684mg, 1.5eq) were added in sequence, and the mixture was reacted at 30°C overnight. After the reaction was completed, the system was cooled to about 5°C with an ice-water bath, and methanol (25mL, 3.57vol) was added dropwise to quench the reaction. The reaction system was concentrated under reduced pressure at 40°C. Purification by hex / EA column chromatography (hex: EA = 3; 1 to EA) gave a light yellow solid (5.3g, yield 82.64%). 1 H NMR (CDCl3, 400MHz) δ7.34~7.24(m,5H),5.02(d,1H),3.88~3.83(m,1H),3.60~3.49(m,4H),2.94~2. 89(m,1H),2.74~2.67(m,1H),2.51~2.47(m,1H),2.23~2.15(m,1H),2.07~2.03(m,1H),1.43(s,9H). LCMS[M+1]=307.47.
[0051] Embodiment 4:
[0052]
[0053] Add SM (1.84g, 1.0eq) to the reaction bottle, add MeOH (18.4mL, 10vol), after the addition, the system is a light yellow clear liquid, and nitrogen is replaced three times. Add Pd(OH)2 / C (0.92g, 0.5g / g) to the system, the system becomes a gray-black turbid liquid, and hydrogen is continuously introduced after hydrogen is replaced three times. After 1h, take the reaction system and dilute it five times with DCM. TLC spot plate, developing agent EA, ninhydrin color raw material (Rf=0.4) disappears. Pad diatomaceous earth (18.4g, 10g / g) and filter, and rinse the filter cake with methanol (55.2mL, 30vol). Concentrate under reduced pressure at 40℃ until there is no fraction to obtain 1.33g of yellow oily product, yield 100%. LCMS[M+1]=217.48.
[0054] Embodiment 5:
[0055]
[0056] Add SM (1.33g, 1.0eq) to the reaction bottle, add THF (6.65mL, 5vol), add water (6.65mL, 5vol) and complete the addition. The system is a light yellow clear liquid, and the nitrogen is replaced three times. Add Na2CO3 (1.30g, 2eq) to the system, there is no obvious temperature rise, the system is slightly turbid, and the ice brine is cooled to 0-10℃. Control the temperature at 0-10℃ and add CbzCl (1.57g, 1.5eq) to the system, and the heat release is obvious (about 3min addition, temperature rise 3℃). Remove the ice brine bath and return to 15-25℃. Stir at 15-25℃ for 16h. White solid precipitates in the system. Take the reaction system DCM and dilute it five times. TLC spot plate, the developing agent DCM: MeOH = 7:1, ninhydrin color, the raw material (Rf = 0) disappears. Water (26.6 mL, 20 vol) was added to the system, and EA (26.6 mL, 20 vol) was added to extract once. The organic phase was concentrated under reduced pressure at 40°C until there was no fraction to obtain a crude product. Wet loading was performed, and silica gel (19.95 g, 15 g / g) was added for column chromatography purification. Hex:EA=10:1-2:1 was used to remove impurities, and Hex:EA=1:1 was used to elute the product. Concentration under reduced pressure gave 1.66 g of a yellow oil with a yield of 77.08%. 1 H NMR (CDCl3, 400MHz) δ7.36~7.29(m,5H),5.12(s,2H),4.82(t,1H),4.13~4.05(m,1H),3 .88~3.84(m,1H),3.68~3.60(m,2H),3.30~3.12(m,2H),2.15~2.09(m,1H),1.44(s,9H). LCMS[M+1]=351.34.
[0057] Embodiment 6:
[0058]
[0059] Add SM (0.3g, 1.0eq) to a 50mL three-necked flask, add DCM (4.11mL, 13.7vol) colorless clear solution, add TEA (0.173g, 2,0eq) to the system, and cool to -10-0℃ with ice brine after addition. Add MsCl (0.13g, 1.304eq) in DCM (0.34mL, 1.14vol) solution to the system at -10-0℃, no obvious heat release, the system is colorless and transparent clear solution, remove the ice brine bath and return to 15-25℃. React at 15-25℃ for 30 minutes, take a sample and dilute with DCM for TLC spot plate detection, the developing agent Hex:EA=1:1, and the ninhydrin color developing material (Rf=0) disappears. The temperature was lowered to 0-15°C, 1N HCl (20 mL, 66.67 vol) was added to the system, and the heat release was obvious. The aqueous phase was separated and extracted once with DCM (10 mL, 33.33 vol), and the organic phases were combined. The organic phase was washed once with saturated brine (10 mL, 33.33 vol), and dried over anhydrous sodium sulfate (0.3 g, 1 g / g). Concentrated under reduced pressure at 40°C until there was no fraction to obtain 337 mg of colorless transparent oil, with a yield of 91.74%. 1 H NMR (CDCl3, 400MHz) δ7.37~7.30(m,5H),5.13(s,2H),4.66(d,1H),4.35~4.31(m,1H),4.23~4.07(m,2H),3.88~3. 84(m,1H),3.79~3.72(m,1H),3.34~3.29(m,1H),3.23~3.17(m,1H),3.04(s,3H),2.52~2.46(m,1H),1.44(s,9H). LCMS[M+1]=429.33.
[0060] Embodiment 7:
[0061]
[0062] Add SM (0.3g, 1.0eq) to a 25mL three-necked flask, add DMF (3mL, 10vol) colorless transparent liquid, replace with nitrogen three times, and cool to 0-10℃ with ice water. Control the temperature at 0-10℃ and add 60% NaH (42.1mg, 1.5eq) to the system without obvious heat release, but obvious gas release. The system becomes a light yellow turbid liquid. Remove the ice water bath and return to 15-25℃. Add water (10mL, 33.33vol) to the reaction system, add EA (10mL, 33.33vol)*2 to extract twice, and combine the organic phases. Dry the organic phase with anhydrous sodium sulfate (0.3g, 1g / g). Concentrate under reduced pressure at 40℃ until there is no fraction to obtain a crude yellow oil. Wet sample, add silica gel (15g, 50g / g), Hex:EA=10:1-1:1 to remove impurities, and elute the product with EA. The mixture was concentrated under reduced pressure at 40°C until no fraction remained, to obtain 164 mg of a light yellow oily product with a yield of 85%. 1 H NMR(DMSO-d6,400MHz)δ7.77(d,1H),7.38~7.31(m,5H),5.07(s,2H),4.41~4.34(m ,1H),4.26~4.18(m,1H),3.70~3.47(m,3H),3.10~2.88(m,2H),2.32~2.23(m,1H). LCMS[M+1]=277.75.
[0063] Embodiment 8:
[0064]
[0065] Add SM (0.2g, 1.0eq) to a 25mL three-necked flask, add THF (2.76mL, 13.8vol) to the system to obtain a colorless clear liquid, replace with nitrogen three times, and cool to 0-10℃ with ice water. Control the temperature at 0-10℃ and add potassium tert-butoxide (128mg, 2.0eq) to the system without obvious heat release. The system is a yellow turbid liquid. Remove the external bath and return to 15-25℃ for 16h. Add water (33mL, 165vol) to the reaction system, add DCM (33mL, 165vol)*2 to extract twice, and combine the organic phases. Dry the organic phase with anhydrous sodium sulfate (0.2g, 1g / g). Concentrate under reduced pressure at 40℃ until there is no fraction to obtain a crude yellow oil. Purify by column chromatography. Concentrate under reduced pressure at 40℃ until there is no fraction to obtain 110mg of a light yellow oil product with a yield of 70%.
[0066] The invention described and claimed herein has many attributes and embodiments, including but not limited to those elaborated or described or cited in detail in the present invention. However, this is not meant to be all-inclusive, and the invention described and claimed herein is not limited to or is not limited by the determined features or embodiments disclosed in detail herein, which are included for the purpose of illustration rather than limitation. It will be readily appreciated by those of ordinary skill in the art that many components and parameters may be changed or modified to some extent, or may be replaced with known equivalents, without departing from the scope of the present invention. It should be understood that these modifications and equivalents are included as if separately set forth. The present invention also includes all steps, features, compositions and compounds mentioned or indicated individually or collectively in this specification, as well as any and all combinations of any two or more of said steps or features.
[0067] All patents, publications, scientific articles, websites and other documents and materials cited or mentioned herein indicate the technical level of technicians in the field to which the present invention belongs, and each document and material cited herein is incorporated by reference to the same extent as if it were incorporated as a whole by individual reference or set forth as a whole herein. The applicant reserves the right to physically incorporate any and all materials and information from any such patents, publications, scientific articles and other reference materials or documents into this specification. The reference to any application, patent and publication in this specification is not and should not be regarded as an admission or any form of suggestion that they constitute valid prior art or constitute part of the common knowledge of any country in the world.
Claims
1. A method for preparing a tetrahydropyrrolooxazinone ring, characterized in that: The tetrahydropyrrolooxazinone ring is in a cis configuration, and its structure is shown in Formula I: The preparation method includes the following synthetic route 1 or synthetic route 2: Synthetic route 1: Synthesis route 2:
2. The preparation method according to claim 1, characterized in that: The specific steps of step 1 are: Maleic anhydride, N-methoxymethyl-N-(trimethylsilyl)benzylamine and trifluoroacetic acid are used as raw materials, dissolved in an organic solvent A and reacted to obtain compound 1; Furthermore, the molar ratio of maleic anhydride, N-methoxymethyl-N-(trimethylsilyl)benzylamine and trifluoroacetic acid is (0.8-1.5):(1.0-2.0):(0.1-1.0), the reaction temperature is 0-10°C, and the organic solvent A is selected from dichloromethane, 1,2-dichloroethane or tetrahydrofuran.
3. The preparation method according to claim 1, characterized in that: The specific steps of step 2 are: Compound 1 is dissolved in organic solvent B, and triethylamine, tert-butyl alcohol and azide are added to mix and a curtius rearrangement reaction is performed to obtain compound 2; Furthermore, the molar ratio of compound 1, triethylamine, tert-butanol and azidation reagent is (0.8-1.5):(1.0-3.0):(3.0-10.0):(1.0-3.0); the reaction temperature is step-wise increased from 10-40°C to 90-120°C; the azidation reagent is selected from diphenylphosphoryl azide, sodium azide or trimethylsilane; and the organic solvent B is selected from toluene, tert-butanol or xylene.
4. The preparation method according to claim 1, characterized in that: The specific steps of step 3 are: Dissolve compound 2, methanol and a reducing agent in an organic solvent C to undergo a reduction reaction to obtain compound 3; Furthermore, the molar ratio of the compound 2, methanol and reducing agent is (0.8-1.5):(0.5-3.0):(1.0-3.0), the organic solvent C is selected from tetrahydrofuran, 2-methyltetrahydrofuran or methanol, and the reducing agent is selected from LiBH4, lithium aluminum hydride or lithium sec-butylborohydride.
5. The preparation method according to claim 1, characterized in that: The specific steps of step 4 are: Compound 3 is dissolved in organic solvent D, and palladium-carbon catalyst is added under hydrogen environment to remove benzyl protection to obtain compound 4; Furthermore, the molar ratio of the compound 3 and the palladium-carbon catalyst is (0.5-1.5): (0.01-1.0); the palladium-carbon catalyst is selected from Pd(OH)2 / C, Pd / C; and the organic solvent D is selected from methanol, ethanol or tetrahydrofuran.
6. The preparation method according to claim 1, characterized in that: The specific steps of step 5 are: Compound 4 is reacted with an amino protecting agent in an organic solvent E under alkaline conditions to obtain compound 5; Furthermore, the molar ratio of the compound 4 to the amino protecting agent and the base is (0.1-1.5): (1.0-2.0): (1.0-4.0); the amino protecting agent is selected from benzyl chloroformate, di-tert-butyl carbonate, (9H-fluoren-9-yl)methyl chloroformate; the base agent is selected from sodium carbonate, triethylamine or potassium phosphate; the organic solvent E is selected from tetrahydrofuran, dioxane or dichloromethane.
7. The preparation method according to claim 1, characterized in that: The specific steps of step 6-1 are: Compound 5 is dissolved in an organic solvent F and reacts with an organic base and methanesulfonyl chloride to undergo a nucleophilic substitution reaction to obtain compound 6; Furthermore, the molar ratio of the compound 5, the organic base and the methanesulfonyl chloride is (0.8-1.5):(1.0-4.0):(1.0-4.0); the organic base is selected from triethylamine, N,N-diisopropylethylamine or dimethylaminopyridine; and the organic solvent F is selected from dichloromethane, tetrahydrofuran or dioxane.
8. The preparation method according to claim 1, characterized in that: The specific steps of step 6-2 are: Compound 5 is added with potassium tert-butoxide in an organic solvent G to react to obtain compound Ⅰ; Furthermore, the molar ratio of the compound 5 to potassium tert-butoxide is (0.8-1.5):(1.0-4.0); the organic solvent G is selected from tetrahydrofuran, 2-methyltetrahydrofuran or DMF; and the reaction temperature is 0-10°C.
9. The preparation method according to claim 1, characterized in that: The specific steps of step 7 are: Compound 6 was reacted by adding 60% NaH in organic solvent H to obtain compound I.
10. The preparation method according to claim 9, characterized in that: The molar ratio of the compound 6 to NaH is (0.8-1.5):(1.0-3.0); the organic solvent H is selected from dimethylformamide, tetrahydrofuran or dimethylacetamide; and the reaction temperature is 0-10°C.
